Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Sell
23
CTTH Quote, Financials, Valuation and Earnings
Last price:
$0.0400
Seasonality move
:
-9.2%
Day range:
$0.0436 - $0.0436
52-week range:
$0.0150 - $0.1518
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.78x
Volume:
--
Avg. volume:
65.6K
1-year change:
118%
Market cap:
$2.5M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, CTT Pharmaceutical Holdings has -- downside to fair value with a price target of -- per share.
CTTH vs. S&P 500
-
Over the past 5 trading days, CTT Pharmaceutical Holdings has underperformed the S&P 500 by -21.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CTT Pharmaceutical Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CTT Pharmaceutical Holdings has grown year-over-year revenues for 0 quarters straight. In the most recent quarter CTT Pharmaceutical Holdings reported revenues of --.
Earnings Growth
-
CTT Pharmaceutical Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CTT Pharmaceutical Holdings reported earnings per share of --.
Enterprise value:
1.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-06-30 | 2017-06-30 | 2018-06-30 | 2017-06-30 | 2018-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$1M | -$434K | -$1.4M | -$139.3K | -$1.1M | |
| EBITDA | -$1M | -$434K | -$1.4M | -$139.3K | -$1.1M | |
| Diluted EPS | -$0.06 | -$0.03 | -- | -$0.01 | -- | |
| Period Ending | 2014-06-30 | 2015-06-30 | 2016-06-30 | 2017-06-30 | 2018-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $227.5K | $958.7K | $179.7K | -- | $995.9K | |
| Total Assets | $227.5K | $1.2M | $179.7K | -- | $995.9K | |
| Current Liabilities | $142K | $196.4K | $361.7K | -- | $293.2K | |
| Total Liabilities | $142K | $196.4K | $361.7K | -- | $336.5K | |
| Total Equity | $85.6K | $986.9K | -$182K | -- | $659.4K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-06-30 | 2017-06-30 | 2018-06-30 | 2017-06-30 | 2018-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $80.1K | -$36.4K | -$183.9K | -$55.4K | -$105.7K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -$104.2K | $154.9K | $1.1M | $1.4K | $995.5K | |
| Free Cash Flow | $80.1K | -$36.4K | -$183.9K | -$55.4K | -$105.7K | |
CTTH
Sector
Market Cap
$2.5M
$33.4M
Price % of 52-Week High
28.72%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
118%
-40%
Beta (5-Year)
0.887
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0475
200-day SMA
Sell
Level
$0.0671
Bollinger Bands (100)
Sell
Level
0.0517 - 0.0917
Chaikin Money Flow
Buy
Level
1.3M
20-day SMA
Sell
Level
$0.0555
Relative Strength Index (RSI14)
Sell
Level
41.1426
ADX Line
Sell
Level
18.9185
Williams %R
Neutral
Level
-65.3631
50-day SMA
Sell
Level
$0.0581
MACD (12, 26)
Sell
Level
-0.0036
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
423.8K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is fast dissolving drug delivery systems through the development of advanced oral delivery thin wafers. The company's technology platform includes the development of advanced oral delivery thin wafers to deliver treatment as an alternate to smoking and ingestion.
Stock Forecast FAQ
In the current month, CTTH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CTTH average analyst price target in the past 3 months is --.
-
Where Will CTT Pharmaceutical Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that CTT Pharmaceutical Holdings share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About CTT Pharmaceutical Holdings?
Analysts are divided on their view about CTT Pharmaceutical Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CTT Pharmaceutical Holdings is a Sell and believe this share price will rise from its current level to --.
-
What Is CTT Pharmaceutical Holdings's Price Target?
The price target for CTT Pharmaceutical Holdings over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CTTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CTT Pharmaceutical Holdings is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CTTH?
You can purchase shares of CTT Pharmaceutical Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CTT Pharmaceutical Holdings shares.
-
What Is The CTT Pharmaceutical Holdings Share Price Today?
CTT Pharmaceutical Holdings was last trading at $0.0400 per share. This represents the most recent stock quote for CTT Pharmaceutical Holdings. Yesterday, CTT Pharmaceutical Holdings closed at $0.0436 per share.
-
How To Buy CTT Pharmaceutical Holdings Stock Online?
In order to purchase CTT Pharmaceutical Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
